Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2017-03-31 Regulatory Filings
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings
2017-03-31 English
AMENDMENT NO 2 PRER14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled as an Amendment No. 2 to a Schedule 14A Proxy Statement filed with the SEC. It is a preliminary proxy statement related to a special meeting of stockholders to approve several proposals including issuance of shares, equity financing, reverse stock split, and adjournment. The document contains detailed descriptions of the proposals, background information, and voting instructions. It is clearly a proxy solicitation document intended to provide information to shareholders to solicit their votes on corporate actions. It is not an annual report, earnings release, or other financial report. It is not a simple announcement or notice but a full proxy statement with detailed information. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2017-03-24 English
Regulatory Filings 2017
Regulatory Filings
2017-03-23 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated March 8, 2017, by Tokai Pharmaceuticals, Inc. The content focuses on a notice of delisting risk due to the company's stock price falling below Nasdaq's minimum bid price requirement. It details the Nasdaq deficiency letter, compliance period, potential transfer to Nasdaq Capital Market, and possible delisting procedures. There are no financial statements or detailed financial data presented, nor is this an announcement of a report publication. The document is an official notice regarding delisting, which matches the definition of a Delisting Announcement (DLST). The document length is 4525 characters, which is sufficient for a substantive announcement rather than a brief report publication announcement. Therefore, the correct classification is DLST with high confidence.
2017-03-09 English
PRER14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A PROXY STATEMENT' and is filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is a preliminary proxy statement related to a special meeting of stockholders to approve issuance of shares, a reverse stock split, and other corporate actions. The document includes detailed descriptions of proposals to be voted on by shareholders and is clearly a solicitation of shareholder votes. It is not an annual report, earnings release, or other financial report. The presence of the term 'proxy statement' and the nature of the content (soliciting votes for corporate actions) aligns with the Proxy Solicitation & Information Statement category. The document length is substantial and contains the full proxy statement, not just an announcement of its availability, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2017-03-09 English
IRANNOTICE
Regulatory Filings Classification · 95% confidence The document is a notice addressed to the U.S. Securities and Exchange Commission referencing a disclosure filed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016. The document itself is short (1059 characters) and serves as a formal notification about the filing of the 10-K report, rather than containing the full annual report or substantive financial data. It is primarily a regulatory notice related to compliance with specific legal provisions (Iran Threat Reduction and Syria Human Rights Act and Exchange Act Section 13(r)). Therefore, it fits best under Regulatory Filings (RNS) as a compliance notification rather than the actual Annual Report (10-K).
2017-03-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.